SUSTAIN: A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance after Induction Chemotherapy or as First-line Treatment Alone or in Combination with Standard of Care Therapies

Type of Cancer
Lung

Site
Bethesda

Protocol Number
CA209370

To Learn More Call
201-510-0910